This webinar will be held live and available on demand.
Thursday, September 19, 2024
11am – 12pm EST
Scientists have developed numerous monoclonal antibody (mAb)-based therapeutics to treat diseases such as cancer, autoimmune diseases, and infectious diseases. Manufacturing these immunotherapeutic drugs requires time-consuming and labor-intensive processes, including isolating B cells, assessing their antibody-producing capacity, and validating the specificity and affinity of the generated mAbs.
In this webinar brought to you by Sartorius, Daryl Cole discusses how new automation platforms can help researchers increase the efficiency and effectiveness of these workflows to optimally generate B cell-based immunotherapies.
Topics Covered
- Comparison of traditional hybridoma technology and modern mAb production methods
- Inherent limitations of traditional antibody discovery approaches
- Benefits of using Sartorius systems for target cell isolation, high-throughput screening and binding characterization
|
Dr. Darryl Cole |
